User:Mr. Ibrahem/Sunitinib

Mr. Ibrahem/Sunitinib
Clinical data
Trade names	Sutent, others
Other names	SU11248
AHFS/Drugs.com	Monograph
MedlinePlus	a607052
License data	EU EMA: by INN; US DailyMed: Sunitinib; US FDA: Sunitinib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Receptor tyrosine kinase (RTK) inhibitor
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	Unaffected by food
Protein binding	95%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	40 to 60 hours (sunitinib); 80 to 110 hours (metabolite)
Excretion	Fecal (61%) and Kidney (16%)
Identifiers
	IUPAC name N-(2-Diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;
Chemical and physical data
Formula	C22H27FN4O2
Molar mass	398.482 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C;
	InChI InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12- ; Key:WINHZLLDWRZWRT-ATVHPVEESA-N ; ; as salt: InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1; Key:LBWFXVZLPYTWQI-IPOVEDGCSA-N;
	(what is this?) (verify)

Sunitinib, sold under the brand name Sutent, is a medication used to treat cancer, specifically renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST), and pancreatic neuroendocrine tumor (pNET).^[2] It is taken by mouth.^[2]

Common side effects include tiredness, fever, nausea, diarrhea, inflammation of the mouth, abdominal pain, swelling, rash, pain, bleeding, and shortness of breath.^[1] Other side effects may include liver problems, osteonecrosis of the jaw, and prolonged QT.^[1] Use during pregnancy may harm the baby.^[1] It is a receptor tyrosine kinase (RTK) inhibitor.^[1]

Sunitinib was approved for medical use in the United States and Europe in 2006.^[1]^[3] In the United Kingdom 4 weeks of medication costs the NHS about £3,100 as of 2021.^[4] In the United States this amount costs about 4,900 USD.^[5]

References edit

^ ^a ^b ^c ^d ^e ^f ^g "SUNItinib Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 15 October 2021.
^ ^a ^b ^c ^d ^e "Sutent- sunitinib malate capsule". DailyMed. Archived from the original on 23 March 2021. Retrieved 7 April 2021.
^ "Sutent". Archived from the original on 12 July 2021. Retrieved 15 October 2021.
^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1058. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
^ "Sunitinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 15 October 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g "SUNItinib Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 15 October 2021.

[PI2021-2] "Sutent- sunitinib malate capsule". DailyMed. Archived from the original on 23 March 2021. Retrieved 7 April 2021.

[EPAR2021-3] "Sutent". Archived from the original on 12 July 2021. Retrieved 15 October 2021.

[BNF80-4] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1058. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[5] "Sunitinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 15 October 2021.

[1]

[2]

[3]

[4]

[5]